In a randomized trial, performance of percutaneous coronary intervention (PCI) at hospitals without cardiac surgery on site was noninferior to PCI performed at hospitals with cardiac surgery on site with respect to mortality at 6 weeks and major adverse cardiac events at 9 months.

This article provides 2-year data on patients with inoperable aortic stenosis randomly assigned to receive standard therapy or transcatheter aortic-valve replacement (TAVR). Death rates at 2 years were higher with standard therapy, but the rate of stroke was higher with TAVR.

Data from a French registry of nearly 3200 transcatheter aortic-valve implantation (TAVI) procedures complement data from randomized clinical trials. This emerging technique shows promise in the treatment of high-risk patients with aortic stenosis.

This study provides 2-year data from the PARTNER trial, in which patients with aortic stenosis received transcatheter aortic-valve replacement (TAVR) or surgical replacement. Overall mortality was similar, but paravalvular leak increased mortality in the TAVR group.

Chronic heart failure is a major cause of illness and death. Heart failure is associated with a hypercoagulable state, formation of left ventricular thrombus, and cerebral embolism.¹,² It is also associated with both sudden death and death resulting from ...

A large PCI registry and a large CABG registry were linked to claims records, with data adjusted for propensity score, to compare clinical outcomes. Patients selected for CABG had a long-term survival advantage over those selected for PCI.

A total of 4752 patients for whom CABG was planned were randomly assigned to undergo the procedure on-pump or off-pump. At 30 days, the rates of death, myocardial infarction, stroke, or renal failure requiring dialysis did not differ significantly between the two groups.

Patients with chest pain have a high hospital admission rate, but often no cardiac cause is found. In this trial, coronary CT angiography accurately identified patients who were free from coronary disease and could be safely discharged from the emergency department.

Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of subsequent cardiovascular death, myocardial infarction, or stroke but increased the rate of moderate or severe bleeding.

In this study of more than 6 million Swedes during 1991–2006, patients were at increased risk for suicide or death from cardiovascular causes after a diagnosis of cancer. Risks were especially high immediately after diagnosis and for cancers with a poor prognosis.

In the treatment of patients with acute pulmonary embolism, the efficacy of rivaroxaban, a factor Xa inhibitor, was similar to that of traditional anticoagulation therapy. There was less bleeding in the group receiving rivaroxaban, which supports its use in the treatment of this condition.